Advisor Partners LLC bought a new stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 754 shares of the biotechnology company’s stock, valued at approximately $207,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of LGND. Principal Financial Group Inc. boosted its stake in Ligand Pharmaceuticals by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 182,606 shares of the biotechnology company’s stock valued at $30,159,000 after purchasing an additional 5,286 shares in the last quarter. Xact Kapitalforvaltning AB boosted its stake in Ligand Pharmaceuticals by 17.4% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 4,058 shares of the biotechnology company’s stock valued at $841,000 after purchasing an additional 600 shares in the last quarter. Boston Advisors LLC bought a new position in Ligand Pharmaceuticals during the 2nd quarter valued at $1,094,000. World Asset Management Inc bought a new position in Ligand Pharmaceuticals during the 2nd quarter valued at $214,000. Finally, Amalgamated Bank boosted its stake in Ligand Pharmaceuticals by 15.5% during the 2nd quarter. Amalgamated Bank now owns 3,417 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 458 shares in the last quarter.

A number of equities analysts have issued reports on the company. Zacks Investment Research raised Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $281.00 price target on shares of Ligand Pharmaceuticals in a research note on Monday, November 5th. Roth Capital raised Ligand Pharmaceuticals from a “neutral” rating to a “buy” rating and decreased their price target for the company from $250.00 to $195.00 in a research note on Monday, October 29th. BidaskClub lowered Ligand Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 27th. Finally, ValuEngine downgraded Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 11th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. Ligand Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $227.00.

In other news, COO Matthew W. Foehr sold 12,000 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $273.88, for a total value of $3,286,560.00. Following the completion of the sale, the chief operating officer now owns 105,388 shares in the company, valued at $28,863,665.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John W. Kozarich sold 2,500 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $275.04, for a total value of $687,600.00. Following the completion of the sale, the director now owns 26,142 shares of the company’s stock, valued at approximately $7,190,095.68. The disclosure for this sale can be found here. Insiders have sold a total of 76,422 shares of company stock valued at $19,791,812 in the last quarter. Insiders own 7.80% of the company’s stock.

Shares of NASDAQ:LGND opened at $151.91 on Friday. Ligand Pharmaceuticals Inc. has a one year low of $126.50 and a one year high of $278.62. The firm has a market cap of $3.28 billion, a PE ratio of 59.11, a P/E/G ratio of 1.36 and a beta of 1.52. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.20 and a quick ratio of 2.19.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its quarterly earnings data on Thursday, November 8th. The biotechnology company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.29. Ligand Pharmaceuticals had a return on equity of 26.17% and a net margin of 73.78%. The company had revenue of $45.66 million during the quarter, compared to the consensus estimate of $41.99 million. During the same quarter in the prior year, the firm earned $0.69 EPS. The company’s quarterly revenue was up 36.8% compared to the same quarter last year. On average, equities research analysts expect that Ligand Pharmaceuticals Inc. will post 5.71 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Advisor Partners LLC Buys Shares of 754 Ligand Pharmaceuticals Inc. (LGND)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/11/16/advisor-partners-llc-buys-shares-of-754-ligand-pharmaceuticals-inc-lgnd.html.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Further Reading: Should I follow buy, hold and sell recommendations?

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.